Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04CRN
|
|||
| Former ID |
DAP000721
|
|||
| Drug Name |
Atomoxetine
|
|||
| Synonyms |
Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Approved | [1], [2] | |
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H21NO
|
|||
| Canonical SMILES |
CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2
|
|||
| InChI |
1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
|
|||
| InChIKey |
VHGCDTVCOLNTBX-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 83015-26-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3249493, 8183809, 11114266, 14749997, 15196878, 34718779, 46506160, 47510014, 48179683, 50070867, 51091800, 57313676, 74924255, 85731218, 85788174, 92714045, 103189006, 104024503, 104305955, 117535667, 126582523, 126629698, 126655720, 126684045, 126723363, 129474852, 134338009, 134358577, 135030248, 137171620, 140098827, 143495940, 152101253, 152234173, 160845669, 160963637, 163773677, 175265837, 178103695, 179151249, 196105295, 223540968, 223682620, 223992935, 225207579, 226420765
|
|||
| ChEBI ID |
CHEBI:127342
|
|||
| ADReCS Drug ID | BADD_D00180 ; BADD_D00181 | |||
| SuperDrug ATC ID |
N06BA09
|
|||
| SuperDrug CAS ID |
cas=083015263
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Inhibitor | [3], [4] |
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7118). | |||
| REF 2 | Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. | |||
| REF 3 | Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. | |||
| REF 4 | New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.